[Skip to Navigation]
From the American Head and Neck Society
November 5, 2020

Expanding Indications for the Human Papillomavirus Vaccine: One Small Step for the Prevention of Head and Neck Cancer, but One Giant Leap Remains

Author Affiliations
  • 1Department of Head and Neck Surgery & Communication Sciences, Duke University, Durham, North Carolina
  • 2Department of Population Health Sciences, Duke University, Durham, North Carolina
  • 3Department of Otolaryngology–Head & Neck Surgery, Medical University of South Carolina, Charleston
  • 4Hollings Cancer Center, Medical University of South Carolina, Charleston
  • 5Department of Otolaryngology–Head & Neck Surgery, University of Minnesota, Minneapolis
JAMA Otolaryngol Head Neck Surg. 2020;146(12):1099-1101. doi:10.1001/jamaoto.2020.4068

In the US, the incidence of human papillomavirus (HPV)–related oropharyngeal cancer (OPC) has been growing at an alarming rate for the past 4 decades.1-3 In 2011, HPV-related OPC was predicted to surpass cervical cancer in annual incidence in the US by 2020.2 However, because of the continued decreasing incidence of cervical cancer and the accelerating incidence of OPC, HPV-related OPC actually surpassed cervical cancer to become the most common HPV-related malignancy in the US in 2015.4 Currently, nearly 19 000 new cases of HPV-related OPC are diagnosed in the US annually.5 The decrease in cervical cancer incidence is partially attributable to effective screening programs and the early detection of precancerous lesions.6 Unfortunately, effective screening tests for precancerous HPV-related lesions of the oropharynx are lacking. Therefore, the best opportunity to curb the epidemic of HPV-related OPC is through vaccination against the oncogenic strains of HPV responsible for OPC.4

Add or change institution
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words